InvestmentMay 4, 2026, 04:04 PM
Hemab Therapeutics Closes IPO, Raises $346.7M Gross Proceeds
AI Summary
Hemab Therapeutics Holdings, Inc. announced the closing of its initial public offering, raising approximately $346.7 million in gross proceeds. The offering included 19,262,500 shares of common stock at $18.00 per share, with underwriters fully exercising their option for an additional 2,512,500 shares. The company's stock began trading on the Nasdaq Global Select Market on May 1, 2026, under the ticker symbol "COAG."
Key Highlights
- Hemab Therapeutics closed its initial public offering of 19,262,500 shares of common stock.
- The public offering price was $18.00 per share.
- Underwriters fully exercised their option to purchase an additional 2,512,500 shares.
- Gross proceeds from the offering totaled approximately $346.7 million.
- Hemab's common stock began trading on Nasdaq Global Select Market on May 1, 2026, under "COAG".